Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine is a synthetic derivative of glutathione, an endogenous tripeptide (gamma-L-glutamyl-L-cysteinylglycine) crucial for cellular antioxidant defense and detoxification. In this derivative, the thiol group of the cysteine residue is modified by the attachment of a 2-iodobenzyl group. This specific chemical modification is expected to alter the compound's biological activity, potentially affecting its interaction with enzymes involved in glutathione metabolism or its role in redox regulation. While glutathione itself is a well-known antioxidant and substrate for various enzymes, this modified form is likely a research chemical or a specific probe designed to investigate particular biological pathways, possibly acting as an enzyme inhibitor or possessing altered pharmacokinetic properties compared to native glutathione.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-Glutamyl[S-(2-iodobenzyl)cysteinyl]glycine.